FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2092681007> ?p ?o ?g. }

• W2092681007 endingPage "959" @default.
• W2092681007 startingPage "953" @default.
• W2092681007 abstract "From the moment an intracranial aneurysm ruptures, cerebral blood flow is impaired, and this impairment mainly determines the outcome in patients who survive after the initial bleeding. The exact mechanism of impairment is unknown, but activation of coagulation and fibrinolysis correlate with clinical condition and outcome after aneurysmal subarachnoid hemorrhage (SAH). The purpose of this study was to determine whether enoxaparin, a low-molecular-weight heparin, which is a well-known anticoagulating agent, has any effect on the outcome of aneurysmal SAH postoperatively.In this randomized, double-blind, single-center clinical trial, 170 patients (85 per group) with aneurysmal SAH were randomly assigned to receive either enoxaparin (40 mg subcutaneously once daily) or a placebo, starting within 24 hours after occlusion of the aneurysm and continuing for 10 days. Analysis was done on an intention-to-treat basis. Outcome was assessed at 3 months on both the Glasgow Outcome and modified Rankin Scales. Patients were eligible for the study if surgery was performed within 48 hours post-SAH, and no intracerebral hemorrhage was larger than 20 mm in diameter on the first postoperative computerized tomography scan. At 3 months, there were no significant differences in outcome by treatment group. Of the 170 patients, 11 (6%) died, and only 95 (56%) had a good outcome. Principal causes of unfavorable outcome were poor initial condition, delayed cerebral ischemia, and surgical complications. There were four patients with additional intracranial bleeding in the group receiving enoxaparin. The bleeding was not necessarily associated with the treatment itself, nor did it require treatment, and there were no such patients in the placebo group.Enoxaparin seemed to have no effect on the outcome of aneurysmal SAH in patients who had already received routine nimodipine and who had received triple-H therapy when needed. Routine use of low-molecular-weight heparin should be avoided during the early postoperative period in patients with SAH, because this agent seems to increase intracranial bleeding complications slightly, with no beneficial effect on neurological outcome." @default.
• W2092681007 created "2016-06-24" @default.
• W2092681007 creator A5005796646 @default.
• W2092681007 creator A5028946529 @default.
• W2092681007 creator A5051498958 @default.
• W2092681007 creator A5068081067 @default.
• W2092681007 creator A5077353876 @default.
• W2092681007 creator A5081738666 @default.
• W2092681007 creator A5081838581 @default.
• W2092681007 creator A5083975407 @default.
• W2092681007 date "2003-12-01" @default.
• W2092681007 modified "2023-10-17" @default.
• W2092681007 title "No effect of enoxaparin on outcome of aneurysmal subarachnoid hemorrhage: a randomized, double-blind, placebo-controlled clinical trial" @default.
• W2092681007 cites W1874700596 @default.
• W2092681007 cites W1972387809 @default.
• W2092681007 cites W1972875444 @default.
• W2092681007 cites W1978595239 @default.
• W2092681007 cites W2012286608 @default.
• W2092681007 cites W2017132043 @default.
• W2092681007 cites W2024118375 @default.
• W2092681007 cites W2034909575 @default.
• W2092681007 cites W2035425314 @default.
• W2092681007 cites W2041585489 @default.
• W2092681007 cites W2048778787 @default.
• W2092681007 cites W2051813950 @default.
• W2092681007 cites W2058775391 @default.
• W2092681007 cites W2060313591 @default.
• W2092681007 cites W2061682653 @default.
• W2092681007 cites W2062553731 @default.
• W2092681007 cites W2065094515 @default.
• W2092681007 cites W2071201445 @default.
• W2092681007 cites W2081957014 @default.
• W2092681007 cites W2086172633 @default.
• W2092681007 cites W2115675051 @default.
• W2092681007 cites W2126003979 @default.
• W2092681007 cites W2151499339 @default.
• W2092681007 cites W2153150897 @default.
• W2092681007 cites W2167603656 @default.
• W2092681007 cites W2313868127 @default.
• W2092681007 cites W2313923699 @default.
• W2092681007 cites W2317448591 @default.
• W2092681007 cites W2333206452 @default.
• W2092681007 cites W2412312127 @default.
• W2092681007 cites W4235754873 @default.
• W2092681007 cites W4241056180 @default.
• W2092681007 cites W4246455918 @default.
• W2092681007 cites W4252748686 @default.
• W2092681007 doi "https://doi.org/10.3171/jns.2003.99.6.0953" @default.
• W2092681007 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14705720" @default.
• W2092681007 hasPublicationYear "2003" @default.
• W2092681007 type Work @default.
• W2092681007 sameAs 2092681007 @default.
• W2092681007 citedByCount "126" @default.
• W2092681007 countsByYear W20926810072012 @default.
• W2092681007 countsByYear W20926810072013 @default.
• W2092681007 countsByYear W20926810072014 @default.
• W2092681007 countsByYear W20926810072015 @default.
• W2092681007 countsByYear W20926810072016 @default.
• W2092681007 countsByYear W20926810072017 @default.
• W2092681007 countsByYear W20926810072018 @default.
• W2092681007 countsByYear W20926810072019 @default.
• W2092681007 countsByYear W20926810072020 @default.
• W2092681007 countsByYear W20926810072021 @default.
• W2092681007 countsByYear W20926810072022 @default.
• W2092681007 crossrefType "journal-article" @default.
• W2092681007 hasAuthorship W2092681007A5005796646 @default.
• W2092681007 hasAuthorship W2092681007A5028946529 @default.
• W2092681007 hasAuthorship W2092681007A5051498958 @default.
• W2092681007 hasAuthorship W2092681007A5068081067 @default.
• W2092681007 hasAuthorship W2092681007A5077353876 @default.
• W2092681007 hasAuthorship W2092681007A5081738666 @default.
• W2092681007 hasAuthorship W2092681007A5081838581 @default.
• W2092681007 hasAuthorship W2092681007A5083975407 @default.
• W2092681007 hasBestOaLocation W20926810071 @default.
• W2092681007 hasConcept C126322002 @default.
• W2092681007 hasConcept C141071460 @default.
• W2092681007 hasConcept C142724271 @default.
• W2092681007 hasConcept C168563851 @default.
• W2092681007 hasConcept C17624336 @default.
• W2092681007 hasConcept C204787440 @default.
• W2092681007 hasConcept C27081682 @default.
• W2092681007 hasConcept C2776098176 @default.
• W2092681007 hasConcept C2776825266 @default.
• W2092681007 hasConcept C2777094939 @default.
• W2092681007 hasConcept C2777736543 @default.
• W2092681007 hasConcept C2777796830 @default.
• W2092681007 hasConcept C2780931571 @default.
• W2092681007 hasConcept C3020199598 @default.
• W2092681007 hasConcept C42219234 @default.
• W2092681007 hasConcept C541997718 @default.
• W2092681007 hasConcept C71924100 @default.
• W2092681007 hasConceptScore W2092681007C126322002 @default.
• W2092681007 hasConceptScore W2092681007C141071460 @default.
• W2092681007 hasConceptScore W2092681007C142724271 @default.
• W2092681007 hasConceptScore W2092681007C168563851 @default.
• W2092681007 hasConceptScore W2092681007C17624336 @default.
• W2092681007 hasConceptScore W2092681007C204787440 @default.
• W2092681007 hasConceptScore W2092681007C27081682 @default.

• next